Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
HMG2 and PLAG1 protein expression in Pleomorphic Adenoma Tumorigenesis and its recurrence and in the progression to Carcinoma ex-Pleomorphic Adenoma
Joint Event on 15th International Congress on American Pathology and Oncology Research & International Conference on Microbial Genetics and Molecular Microbiology
The Pleomorphic Adenoma (PA) is the most common neoplasm of salivary glands. Recurrences of APs are common and
increase the probability of the malignant transformation giving rise to the Carcinoma Ex Pleomorphic Adenoma (CXPA),
which, although rare, is an aggressive tumor with frequent metastasis and death related to the disease. As previously reported in the
literature, the Pleomorphic Adenoma Gene 1 (PLAG1) and High Mobility Group AT-hook 2 (HMGA2) genes are associated with
the onset and progression of PAs and CXPAs. HMGA2 plays a role in the architectural transcription factor, modulating the threedimensional
conformation of the DNA and consequently modulating the expression of several genes. The PLAG1 gene is involved
in cell proliferation through the control of various target genes. In normal tissues, its activity is high during embryonic and fetal
development, but in adult life, however, its participation is low or absent. The protein expression of PLAG1 and HMGA2 in 38 cases
of PA, 36 cases of Recurrent PA (RPA) and 41 cases of CXAP was analyzed. The histological subtype and degree of tumor progression
were considered. A significant association of PLAG1 with PAs was found (89.5%), while the HMGA2 gene protein was presented with
a relevant association with the malignant counterpart of the disease (48.78%). A higher prevalence of HMGA2 protein expression
in high grade and aggressive tumors considering the histological subtype and degree of tumor progression was observed. PLAG1
protein expression was lower when PA underwent malignant transformation, possibly due to other pathway activation and different
clone cells. In addition, PLAG1 protein expression was present mainly in low-grade carcinomas and in cases with the early phase of
invasion probably due to its property of regulation of oncogene-induced cell senescence. In CXPA, PLAG1 expression was mostly
associated with myoepithelial differentiation. This way, the loss of PLAG1 protein expression can be considered a hallmark of CXPA
carcinogenesis, mainly when there is only epithelial differentiation. Our study showed that these genes are promising targets for more
effective therapies and consequently lower morbidity due to these neoplasms.